Our data indicated that CD8+ T cells in response to the activation of the DC/tumor fusion vaccine and LPS‐Nb36 retarded tumor growth and strengthened survival of xenografted mice, which performed better treatment results than other groups (Fig. 6A). The gene discussed is CD8A; the disease is neoplasm.